Please ensure Javascript is enabled for purposes of website accessibility

This Top Beer Maker Is Going to Produce Cannabis Beverages This Year

By David Jagielski – Sep 8, 2021 at 8:12AM

Key Points

  • Despite a high growth rate, the cannabis beverage market remains fairly small. But that hasn't stopped many companies from getting involved.
  • Boston Beer has partnered with multiple marijuana companies to produce beverages.
  • Given the big players already in the relatively small sector, it's not likely to be a significant source of revenue for the company.

Motley Fool Issues Rare “All In” Buy Alert

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Boston Beer created a subsidiary earlier this year to focus on the cannabis market.

The cannabis beverage market possesses some attractive growth opportunities for businesses. Analysts from Grand View Research expect that the global market will rise in value at a compounded annual growth rate of 17.8% over the next few years and be worth $2.8 billion by 2025. Getting an early position in the sector could allow businesses to benefit from strong market share later on.

Some of the world's top beer makers are already showing an interest in it, including Constellation Brands, which has partnered with Canopy Growth to produce beverages. Anheuser-Busch, known for its popular Budweiser brand, has a joint venture with Tilray. Similarly, beverage company Molson Coors has also been developing drinks with cannabis producer Hexo.

Investors can now add another big beverage company to the list, as The Boston Beer Company (SAM -0.42%) plans on producing cannabis-infused drinks before the end of this year.

Group of friends with glasses of beer sitting around a table.

Image source: Getty Images.

Subsidiary of Boston Beer reaches an agreement with two other companies

Earlier this year, Boston Beer created a subsidiary, BBCCC, which is based in Ontario and will focus on non-alcoholic cannabis beverages. On Aug. 31, the subsidiary announced that it would be partnering with marijuana companies WeedMD and Peak Processing Solutions to begin producing cannabis-infused beverages in the fourth quarter. The deal is good for five years, and Boston Beer will benefit from Peak's production facilities. Entourage Health (the parent company of WeedMD) will be the exclusive distributor; it has access to 95% of the retail cannabis market in Canada.

Boston Beer said in May, when it announced it would be creating the cannabis subsidiary, that "we believe non-alcoholic cannabis beverages could represent a new frontier of innovation and want to be ready for future opportunities in the US." Although this deal doesn't involve selling cannabis-infused beverages in the U.S. market, it could certainly lead to that down the road. Given the federal ban on marijuana in the U.S., producing beverages in Canada (where pot is legal federally) is an option that will allow Boston Beer to get started on cannabis beverages immediately. While cannabis beverages are sold in some states in the U.S., those products can't cross state lines; producing cannabis beverages in Canada is just an easier option right now.

Is the field already getting too crowded?

As investors will likely note from the relatively small market size of the global cannabis beverage industry, this is a sector of cannabis that is still in its infancy. While it will be a good testing ground for Boston Beer to bring products to market and test them out, it likely won't lead to much revenue for the business. 

Canopy Growth, which was one of the first cannabis companies to express an interest in beverages, hasn't been generating a whole lot of revenue from that area of its business. In fact, that company doesn't even separate out cannabis beverages on its income statement. Instead, it groups them with edibles, topicals, and vapes. Even combined, that line item generated just 13 million Canadian dollars' worth of sales during the period ending June 30 -- less than 10% of its top line. Hexo reported cannabis beverage sales of over CA$3 million for the period ending April 30.

Does this move make Boston Beer a buy?

Boston Beer reported net revenue of $602.8 million in its latest quarter (the period ending June 26), meaning any cannabis-related revenue it generates will likely have a minimal impact on its financials. It's a way for the company to expand its product line in preparation for a potentially larger market in the future, but it shouldn't be a reason to invest in the stock if you weren't already planning to do so. With many analysts expecting its shares to rise by more than 70% --and given the benefits that could come from a hot market for hard seltzer, including its Truly brand -- Boston Beer could make for a solid investment. Just don't expect cannabis to play a big role in that for the time being.

David Jagielski has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Constellation Brands. The Motley Fool recommends Anheuser-Busch InBev NV, Boston Beer, and HEXO Corp. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Boston Beer Stock Quote
Boston Beer
SAM
$375.50 (-0.42%) $-1.57
Constellation Brands Stock Quote
Constellation Brands
STZ
$257.50 (0.00%) $0.01
Anheuser-Busch Companies, LLC Stock Quote
Anheuser-Busch Companies, LLC
BUD
Canopy Growth Corp. Stock Quote
Canopy Growth Corp.
CGC
$3.40 (-7.10%) $0.26
Tilray, Inc. Stock Quote
Tilray, Inc.
TLRY
$3.65 (-5.20%) $0.20

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
356%
 
S&P 500 Returns
118%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/29/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.